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ABSTRACT
Introduction Acute exacerbations of chronic obstructive 
pulmonary disease (AECOPD) are the most critical events 
for patients with COPD that have a negative impact on 
patients’ quality of life, accelerate disease progression, 
and can result in hospital admissions and death. Although 
there is no distinct definition or detailed knowledge about 
AECOPD, it is commonly used as primary outcome in 
clinical studies. Furthermore, it may be difficult in clinical 
practice to differentiate the worsening of symptoms due 
to an AECOPD or to the development of heart failure. 
Therefore, it is of major clinical importance to investigate 
the underlying pathophysiology, and if possible, predictors 
of an AECOPD and thus to identify patients who are at high 
risk for developing an acute exacerbation.
Methods and analysis In total, 355 patients with COPD 
will be included prospectively to this study during a 
3- week inpatient pulmonary rehabilitation programme 
at the Schoen Klinik Berchtesgadener Land, Schoenau 
am Koenigssee (Germany). All patients will be closely 
monitored from admission to discharge. Lung function, 
exercise tests, clinical parameters, quality of life, physical 
activity and symptoms will be recorded, and blood samples 
and exhaled air will be collected. If a patient develops an 
AECOPD, there will be additional comprehensive diagnostic 
assessments to differentiate between cardiac, pulmonary 
or cardiopulmonary causes of worsening. Follow- up 
measures will be performed at 6, 12 and 24 months.
Exploratory data analyses methods will be used for the 
primary research question (screening and identification 
of possible factors to predict an AECOPD). Regression 
analyses and a generalised linear model with a binomial 
outcome (AECOPD) will be applied to test if predictors are 
significant.
Ethics and dissemination This study has been 
approved by the Ethical Committee of the Philipps 
University Marburg, Germany (No. 61/19). The results will 
be presented in conferences and published in a peer- 
reviewed journal.
Trial registration number NCT04140097.
INTRODUCTION
Chronic obstructive pulmonary disease 
(COPD)1 is a lung disease characterised by respi-
ratory problems and poor airflow with dyspnoea 
and cough being the main symptoms leading to 
impaired exercise performance and quality of 
life.2 COPD is a progressive disease that typically 
worsens over time.2 In this context, acute exac-
erbations of COPD (AECOPD) are the most 
critical events for patients with COPD, essential 
for the clinical course and the prognosis. The 
American Thoracic Society and the European 
Respiratory Society define AECOPD clinically as 
an episode of increased respiratory symptoms, 
particularly dyspnoea, cough, sputum produc-
tion and increased sputum purulence.3 These 
issues are also reflected in the Global Initiative 
for Chronic Obstructive Lung Disease (GOLD) 
Strengths and limitations of this study
 ► To the best of our knowledge, this is the largest 
chronic obstructive pulmonary disease (COPD) co-
hort with prospectively collected data to investigate 
the development of an acute exacerbation.
 ► A large variety of assessments including basic sci-
ence approaches will be used to detect potential 
early predictors for an acute exacerbation.
 ► Acute exacerbation diagnosis will be based on 
clinical signs and judged by an experienced 
pulmonologist.
 ► This is the first study to differentiate between 
COPD- related exacerbation and cardiac- related 
exacerbation.
 ► This study is based on exploratory data anal-
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strategy, which defines an exacerbation as ‘an acute worsening 
of respiratory symptoms that results in additional therapy’.2 
It is assumed that the majority of AECOPD are triggered 
by infections mainly with respiratory viruses4 or pathogenic 
bacteria5 which increase local and systemic inflammation.6 
Exacerbations have a negative impact on the quality of life of 
patients with COPD,7 accelerate disease progression, and can 
result in hospital admissions and death.8 9 Also within health-
care systems significant variability exists between physicians 
in both diagnostic practices and prescribing habits at exacer-
bations,10 and the utility of biomarkers to guide clinicians in 
exacerbation diagnosis and treatment is currently limited.11 12
Furthermore, physical comorbidities, such as cardio-
vascular disease, are also often prevalent in patients with 
COPD13 and are an additional challenge that impacts clini-
cians’ decision- making at COPD exacerbation.14 In patients 
with COPD with concomitant cardiovascular disease, exacer-
bations confer an increased risk of subsequent cardiovascular 
disease events, especially in hospitalised patients and within 
the first 30 days post- exacerbation.15
Until now, research in the field of AECOPD has gathered 
and analysed data usually after manifestation of AECOPD 
until recovery and most of them used a retrospective study 
design.16 17 A recent systematic review on the monitoring of 
physiological parameters (eg, oxygen saturation, heart rate 
or respiratory rate) to predict an AECOPD concluded that 
there is currently insufficient information on how physiolog-
ical parameters vary prior to exacerbation to support routine 
domiciliary monitoring for the prediction of AECOPD.18 It 
would be of extreme clinical importance to determine early 
predictors of an AECOPD and to identify patients who are 
at high risk for developing an acute exacerbation and/or to 
detect the beginning of or prevent an acute exacerbation as 
early as possible. Early predictors of AECOPD could help to 
develop novel therapeutic treatment options and strategies, 
to prevent acute exacerbations in the future for patients with 
COPD.
METHODS AND ANALYSIS
Study design and registration
This study will be a monocentric, prospective observational 
study. Patients will be recruited during an inpatient pulmo-
nary rehabilitation programme at the reference centre of the 
Philipps University Marburg: Schoen Klinik Berchtesgadener 
Land at Schoenau am Koenigssee (Germany). From an 
own former retrospective analysis in 401 patients with very 
severe COPD, we learnt that 15.2% of these patients develop 
an AECOPD during their stay in the clinic.19 Therefore, 
the setting of an inpatient pulmonary rehabilitation offers 
a unique model to study the phenomenon of an AECOPD 
prior to the first visible clinical sign and further on to have 
a follow- up of the underlying mechanisms. All patients with 
COPD who are referred to the reference centre for a rehabil-
itation programme will be included after providing written 
informed consent. Prospectively, a wide range of measure-
ments will be collected (figure 1). If a patient develops 
an AECOPD, there will be an additional comprehensive 
diagnostic assessment to differentiate between pulmonary, 
cardiac or cardiopulmonary reasons for the acute exacerba-
tion (table 1). The diagnosis of an AECOPD will be made 
clinically by an experienced pulmonologist within the first 24 
hours according to the Anthonisen criteria with the occur-
rence of at least two symptoms among sputum volume, 
sputum purulence and breathlessness.20
Study objectives
Primary endpoint
To prospectively identify potential early, respiratory and 
or cardiac clinical predictors, laboratory parameters, 
breath print analyses and/or changes in lung function, 
symptoms and physical activity prior to an AECOPD in 
patients with COPD.
Secondary endpoint(s)
 ► To identify potential mechanisms explaining the 
nature and composition of an acute exacerbation in 
patients with COPD.
 ► To identify and differentiate patterns of acute COPD 
exacerbation versus cardiac failure in patients with 
COPD.
 ► To investigate the potential role of exhaled breath vola-
tile organic compound (VOC) profiles for the early 
detection of an AECOPD (‘COPD pre- exacerbation 
breath print’).
 ► To use an electronic nose to capture exhaled breath 
metabolomic profiles for the early detection of an 
acute exacerbation in patients with COPD (‘COPD 
pre- exacerbation breath print’).
 ► To identify parameters influencing mortality and 
other adverse events in the total study cohort at 6, 12 
and 24 months’ follow- up.
Recruitment period
The study started with the first- patient- in in February 
2020 and is scheduled for last- patient- out by the end of 
2023 (followed by the 6, 12 and 24 months’ follow- up 
measures).
Eligibility criteria
Inclusion criteria: patients referred to an inpatient pulmo-
nary rehabilitation programme at the Schoen Klinik 
Berchtesgadener Land (Germany) with a confirmed 
diagnosis of COPD according to GOLD stage II–IV,2 the 
ability to follow the rehabilitation protocol and a provided 
written informed consent.
Exclusion criteria: patients with an ongoing AECOPD 
or a current primary diagnosis of asthma will not be 
included in the study.
Study measures and outcomes
Baseline characteristics
The following baseline characters will be recorded at 
study baseline concerning:
 ► Age, gender, anthropometrics.
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 ► Social status (family, children), education (years of 
school and job training), employment status (full- 
time, half- time, pension).
 ► Smoking status (active smoker, ex- smoker, never 
smoker).
 ► Number of pack years (1 pack year=1 daily smoked 
pack of cigarettes for 1 year).
 ► Long- term oxygen therapy (yes/no, daily usage dura-
tion and prescription since when).
 ► Frailty status according to Fried Frailty Index.21
Figure 1 Study flow chart. AECOPD, acute exacerbation of chronic obstructive pulmonary disease; AEs, adverse events; PR, 
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Table 1 Overview on study measures
Measures Baseline PR period
On day 1+5 during 
an AECOPD event End of PR
Follow- up 6, 12, 24 
months post- PR
Patients’ characteristics   
  Anthropometry, regular 
drug treatment, education, 
social status, frailty status, 
comorbidities, number of 
AECOPD, number of hospital 
admissions during the past year 
due to an AECOPD, smoking 
status, frequency of regular 




x         
Medication during AECOPD   
  Documentation of drugs during 
AECOPD
    X
(day 1 of AECOPD)
    
Lung function diagnostics   
  Bodyplethysmography, blood gas 
analysis
x   x x x   
Basic diagnostics   
  Bioelectrical impedance analysis x         
Breath sampling   
  VOC breath print by GC/MS and 
IMS analysis
Twice weekly   
Cardiac parameters           
  Doppler echocardiography left 
and right heart
x   x x x   
  Pulse wave velocity, intima- media 
diameter, Ankle- Brachial Index
x         
  Electrocardiography x   X
(day 1 of AECOPD)
    
Laboratory parameters   
  CRP, NT- proBNP x   x x x   
  Fasting cortisol x     x   
  NT- proBNP, troponin, CRP 
(bedside tests),
  troponin, creatine kinase, creatine 
kinase MB
    X (day 1)     
  Fibrinogen, D- dimer x   x x x (only in AE)   
  Blood glucose level (day 
profile: morning (fasting), noon, 
afternoon)
    X (day 3)     
  HbA1c, alpha-1 antitrypsin serum 
level
x         
  Procalcitonin     x x     
  Virus serology x   x (day 1)   x
(day 42 post- AE)
Virus analysis   
  Nasopharyngeal swabs x   X (day 1) x (only in AE)   
Exercise tests   
  6 min walk test (incl. BGA), sit- 
to- stand test, peak quadriceps 
force, handgrip strength
x     x   
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 ► Comorbidities according to the criteria by Vanfleteren 
et al.13
 ► Nocturnal non- invasive ventilation (yes/no, daily 
usage duration and prescription since when).
 ► Nocturnal transcutaneous partial pressure of carbon 
dioxide measurement (Sentec Digitall Monitoring 
System) in case of hypercapnia to record CO2 max, 
SpO2 min).
 ► Number of hospitalisations (with reason) and acute 
exacerbations within the last year and total so far.
 ► Patient already attended a disease management 
programme like, for example, COBRA (yes/no).
 ► Number of previous pulmonary rehabilitation 
programmes.
 ► Frequency of regular physical exercise training 
(content, days per week and duration) and amount 
of physical activity (using Physical Activity Vital Sign 
questionnaire.
Bodyplethysmography and blood gas analysis
Initial measures of bodyplethysmography on day 1 will be 
performed after medication use. Blood gas analyses will 
be performed at rest under ambient conditions after at 
least 10 min of quiet sitting. Samples will be taken from 
the hyperaemic earlobe.
Bioelectrical impedance analysis
Body composition (fat- free mass) will be measured using 
bioelectrical impedance (NutriGuard- M, Data Input 
GmbH, Germany).22
Breath VOC analysis
Inflammatory phenotyping in patients with chronic 
airway disease can be made through blood or sputum 
analysis.23 These assessments do not provide results in real 
time because they require laboratory procedures. Hence, 
efforts are ongoing to bring biological assessment to the 
point of care. If properly validated, molecular profiling 
of exhaled air may provide a non- invasive and rapid alter-
native for blood and sputum.24 VOCs in exhaled air have 
been associated with inflammatory profiles in asthma25 26 
and COPD.27 For VOC analysis 2, different approaches 
will be used:
1. Analysis by ion- mobility spectrometry (IMS) (BioScout 
IMS, B&S Analytik, Dortmund, Germany) will be per-
formed. The IMS technology is fast and easy to use. 
Patients exhale directly into the IMS device where only 
low volumes of exhalation are needed for analysis. IMS 
has a great potential to proceed to become a point- of- 
care tool that produces characteristic disease- related 
breath profiles.28
2. Analysis by gas chromatography/mass spectrometry 
(GC/MS): we will collect breath samples on adsorption 
tubes for the analysis by GC/MS,29 30 using the novel 
ReCIVA sampler system (Owlstone medical, UK). The 
patients will inhale precleaned pressurised room air 
and the adsorption tubes will be loaded with 500 mL 
of exhaled breath. The tubes will then be shipped to 
Fraunhofer ITEM (Hannover, Germany) for GC/MS 
analysis.
Measures Baseline PR period
On day 1+5 during 
an AECOPD event End of PR
Follow- up 6, 12, 24 
months post- PR
  COPD Assessment Test x   x x x x
Health- related quality of life II   
  36- item Short Form Health 
Survey, mMRC score, COPD 
Angst Fragebogen, PHQ-9
x     x x
Self- reported daily patients’ diary 
(EXACT)
  
  Daily rating of symptoms   x       
Physical activity monitoring 
(ActiGraph)
  
  Continuous monitoring via activity 
tracker plus asking for frequency 
of regular physical exercise 
training
  x     x
(1 week only in AECOPD 
plus n=50 non- AECOPD)
Telephone interview (6, 12, 24 
months)
  
  Quality of life I and II, 
hospitalisations, mortality
        x
AE, adverse event; AECOPD, acute exacerbation of chronic obstructive pulmonary disease; BGA, blood gas analysis; CRP, C reactive protein; 
EXACT, EXAcerbations of Chronic pulmonary disease Tool; GC/MS, gas chromatography/mass spectrometry; HbA1c, haemoglobin A1c; IMS, 
ion- mobility spectrometry; mMRC, Modified Medical Research Council; NT- proBNP, N- terminal probrain natriuretic peptide; PHQ-9, Patient Health 
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It can be assumed that the clinical change from stable 
to exacerbated patients with COPD independent of the 
cause of the exacerbation will change the pattern of 
exhaled VOCs in patients with COPD.31 The early detec-
tion of these changes and a respective adjustment of 
treatment could potentially avoid the number of COPD 
exacerbations. Based on VOC pattern and clinical charac-
teristics, COPD phenotypes could be defined.
Cardiovascular assessment
Echocardiography will be performed to assess morphology 
and function of the left and right heart, including 
Doppler flow measurements. The intima- media diameter, 
the pulse wave transit time and the Ankle- Brachial Index 
will be assessed. In case of an AECOPD, a resting electro-
cardiography will be performed.
Virus analyses
Nasopharyngeal swabs will be collected by means of nylon 
flocked swabs in combination with universal transport 
medium- RT (Copan Diagnostics, Murrieta, California, 
USA) and stored at −80°C. Viral RNA will be extracted with 
a QIAamp viral RNA purification kit (Qiagen, Valencia, 
California, USA) and tested by PCR for the determina-
tion of the most common respiratory viruses (including 
SARS- CoV-2, respiratory syncytial virus, influenza A, influ-
enza B, rhinovirus, human metapneumovirus, adenovirus, 
human bocavirus). Moreover, whole genome sequencing 
of the same samples will be processed by next generation 
sequencing for analyses of the virome.
Venous blood samples
Basic inflammatory parameters will be analysed directly. 
Furthermore, blood samples will be frozen at −80°C 
and stored for further comprehensive analysis on, for 
example, virus- induced reasons for an AECOPD and a 
variety of clinically relevant serological parameters being 
able to modulate inflammatory processes (eg, interleu-
kins, tumour necrosis factor- alpha).
Exercise testing
 ► Six- minute walk test (6MWT) including blood gas 
analyses pre/post- 6MWT will be performed in accord-
ance with international recommendations.32
 ► Sit- to- stand tests (STSTs).
STSTs involve either the number of sit- to- stand repe-
titions from a standard chair within 1 min (1 min 
STST),33 or quantify the time that a patient needs to 
perform five repetitions in a row (5- repetition STST).
 ► Peak quadriceps force.
Isometric peak quadriceps force will be measured at 
90° knee angle using a fixed dynamometer on a knee- 
extension training device. At least three attempts 
will be performed with the best value in Newton and 
%pred. being recorded.34
 ► Peak handgrip force.
Isometric peak handgrip force will be measured by 
handheld dynamometry (JAMAR hydraulic hand 
dynamometer) in a 90° elbow angle position. At least 
three attempts will be performed with the best value 
in kilogram and %pred.35 are recorded.
Quality-of-life measures
 ► The 36- item Short Form Health Survey.
Generic health- related quality- of- life (HRQL) 
measure. The instrument is used widely to evaluate 
HRQL across various populations.36 There are two 
summary scales: an overall physical and a mental 
health component summary score.
 ► COPD Assessment Test (CAT).
The CAT is a patient- completed questionnaire 
assessing the global impact of COPD on health status 
with scores <10 indicating low, 10–20 medium, 21–30 
high and >30 very high influence on health status.37
 ► COPD Angst Fragebogen (CAF).
The CAF questionnaire is a reliable and valid question-
naire to determine COPD- specific anxiety according 
to the following domains: social isolation, dyspnoea, 
physical activity, disease progression, partnership and 
long- term oxygen therapy.
 ► Patient Health Questionnaire-9 (PHQ-9).
The PHQ-9 is a self- administered patient question-
naire that monitors the severity of depression and 
response to treatment (score: 0–27).
 ► Modified Medical Research Council score (mMRC 
score).
The mMRC score is a simple grading system for 
patients with respiratory diseases, to assess degree of 
baseline functional disability due to dyspnoea.
Self-reported patient diary (EXAcerbations of Chronic pulmonary 
disease Tool-patient-reported outcome)
The EXAcerbations of Chronic pulmonary disease Tool 
is a 14- item patient- reported outcome daily diary used 
to quantify and measure exacerbations of COPD.1 It 
provides a simple, standardised approach for assessing 
the symptomatic manifestations of COPD exacerbations, 
with a development and validation history consistent with 
guidelines proposed by the Food and Drug Administra-
tion, and well- established measurement principles.
Physical activity monitoring
Physical activity will be measured using the GT3X+device 
from ActiGraph, a validated device in COPD.38 The device 
includes both a microelectromechanical system- based 
accelerometer and an ambient light sensor. Average steps 
per day as well as time spent in different physical activity 
levels during the day (low, moderate, vigorous) will be 
analysed.
Follow-up measures (at 6, 12, 24 months)
Following outcomes will be reassessed at the follow- up 
measures: number of hospitalisations, number of 
AECOPD, quality of life, amount of regular exercise 
training and physical activity monitoring (in a subgroup). 
Furthermore, if patients die during the follow- up period, 
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Safety evaluation
The clinic has an established protocol for managing 
patients if they develop an exacerbation during the 
programme. This protocol will be followed for the 
patients admitted to this study. In case of an AECOPD, 
patients are clinically diagnosed by a pulmonologist and 
treated according to international guidelines.3 In case of 
a life- threatening deterioration, patients are referred to 
an acute hospital. Otherwise, the AECOPD treatment is 
continued during the inpatient pulmonary rehabilitation 
(PR) programme or at an intermediate care room under 
close monitoring at the recruitment centre. Adverse 
events during the PR phase will be recorded in the elec-
tronic case report form (e- CRF).
Sample size estimation and recruitment target
In a previously presented analysis of pretransplant patients 
with COPD (n=401), 15% developed an AECOPD during 
the inpatient rehabilitation period.19 Therefore, we aim 
to include 355 patients with COPD in this study to end 
up with an adequate cohort of about 50 patients with 
AECOPD for further exploratory data analyses.
The recruiting reference centre (University of Marburg 
Teaching Hospital Schoen Klinik Berchtesgadener Land) 
represents a unique setting for this comprehensive obser-
vational study including diagnostic and scientific exper-
tise. In 2018, a total of 300 patients with COPD have been 
referred to this centre. Due to staff and logistic reasons, 
only every second patient (according to the running 
patient ID) will be assessed for eligibility. It is very likely 
that the estimated sample size can be recruited within 
36 months. A refusal rate of about 20% (95 out of 450 
patients who will be assessed for eligibility) is in accor-
dance to our own centre- based study experience with 
patients with COPD. Also, a dropout rate of about 20% 
must be expected (based on study centre experiences). 
Reasons for dropout will be recorded.
Patient and public involvement
Prior to the study, we have interviewed several patients 
with frequent AECOPD in our clinic asking for early signs 
of AECOPD. We could not elaborate individual predic-
tors for AECOPD. Asking for the importance, patients 
generally described AECOPD as the most frightening 
event markedly influencing their quality of life.
The public was not involved in planning this study.
Statistical analyses
Data will be stored and managed in a password- secured 
e- CRF (MACRO database) managed by the Coordi-
nating Centre for Clinical Trials of the Philipps Univer-
sity Marburg. Professional data management will also 
be provided by this institution. Data consistency will be 
checked and data will be screened for outliers, normality, 
gamma or lognormal distributions by using quantile 
plots. Continuous variables will be tested for the above- 
mentioned distributions by using Kolmogrov- Smirnov 
test. Cross- tabulation tables will be analysed using Fisher’s 
exact test or Pearson’s Χ2 test. Exploratory data analyses 
methods will be used for the primary research ques-
tion (screening and identification of possible factors to 
predict an AECOPD). Univariate correlation (Pearson or 
Spearman) and regression analyses will be used to restrict 
the large number of possible predictors in the first step; 
and then in the second step, this restricted set will be 
offered to a forward variable selection algorithm to end 
up with an even smaller set. Finally, this smaller set will 
be analysed by a generalised linear model with a bino-
mial outcome (AECOPD) which will test if predictors are 
significant. Secondary research questions will be analysed 
by using mixed models or generalised estimation equa-
tion models which offer modelling of normal, gamma 
or lognormal distributions. In case of deviations of these 
distributions, Friedman analysis of variance, Wilcoxon 
matched pairs test as non- parametric alternatives will be 
used. It will be clearly stated in the Discussion section of 
the final manuscript as a limitation of the study that the 
analysis is based on exploratory data analyses methods 
without a sample size or power computation. All reported 
tests will be done two- sided, and p values of <0.05 will be 
considered as statistically significant. All statistical anal-
yses will be done by the use of NCSS (NCSS V.10, NCSS, 
Kaysville, Utah, USA), STATISTICA V.13 (Hill, T & 
Lewicki, P. Statistics: Methods and Applications. StatSoft, 
Tulsa, Oklahoma, USA).
Ethics and dissemination
This study has been approved by the Ethical Committee of 
the Philipps University Marburg, Germany (no. 61/19). 
There are no safety considerations.
The results of this study will be disseminated by different 
complimentary strategies:
1. Publication of study results in high- quality internation-
al peer- reviewed journals.
2. Presentation and discussion of study results during na-
tional and international conferences and congresses.
3. Sharing results with national and international clinical 
networks and medical societies.
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